Carlo Ferraro — Movement Disorder Researcher

Carlo Ferraro, MD — Movement Disorder Researcher

Carlo Ferraro, MD is an Italian neurologist and professor specializing in movement disorders and neurodegenerative diseases, with particular expertise in [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Multiple System Atrophy](/diseases/multiple-system-atrophy) (MSA), and atypical parkinsonian syndromes. He is affiliated with the Department of Biomedical and Neuromotor Sciences (DIBINEM) at the [University of Bologna](https://www.unibo.it/) and the IRCCS Istituto delle Scienze Neurologiche in Bologna, Italy — one of Italy's leading centers for movement disorder research and clinical care. Dr. Ferraro's research encompasses clinical phenotyping, neuroimaging biomarkers, autonomic dysfunction, and therapeutic advances in atypical parkinsonisms, with a particular focus on prospective cohort studies of Italian patients.

Academic Background and Training

Carlo Ferraro, MD — Movement Disorder Researcher

Carlo Ferraro, MD is an Italian neurologist and professor specializing in movement disorders and neurodegenerative diseases, with particular expertise in [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Multiple System Atrophy](/diseases/multiple-system-atrophy) (MSA), and atypical parkinsonian syndromes. He is affiliated with the Department of Biomedical and Neuromotor Sciences (DIBINEM) at the [University of Bologna](https://www.unibo.it/) and the IRCCS Istituto delle Scienze Neurologiche in Bologna, Italy — one of Italy's leading centers for movement disorder research and clinical care. Dr. Ferraro's research encompasses clinical phenotyping, neuroimaging biomarkers, autonomic dysfunction, and therapeutic advances in atypical parkinsonisms, with a particular focus on prospective cohort studies of Italian patients.

Academic Background and Training

Dr. Ferraro completed his medical degree and neurology residency at the University of Bologna, one of Europe's oldest and most distinguished medical schools. Following his training, he joined the movement disorder unit at Bologna, which has a long tradition of research into atypical parkinsonisms, including seminal work on MSA and PSP by the group led by Professor Pietro Cortelli.

His clinical and research career has been dedicated to understanding the clinical heterogeneity of parkinsonian disorders, the development of diagnostic biomarkers, and the characterization of disease progression in disorders that are often difficult to distinguish from each other and from [Parkinson's Disease](/diseases/parkinsons-disease). His position at a tertiary referral center gives him access to a large cohort of well-characterized patients, enabling prospective studies that have contributed significantly to the field.

Research Areas

Clinical Characterization of PSP Variants

A central focus of Dr. Ferraro's research has been the systematic clinical characterization of [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) phenotypes using prospective cohort studies. His 2024 paper, "Clinical features of PSP variants: a prospective Italian cohort study," examined a well-characterized cohort of Italian patients to identify distinctive clinical patterns across PSP subtypes[@ferraro2024clinical].

The study differentiated between classic Richardson syndrome, PSP-Parkinsonism (PSP-P), PSP with predominant cerebellar ataxia (PSP-C), PSP with pure akinesia and gait freezing (PSP-PAGF), and PSP-Corticobasal Syndrome (PSP-CBS), characterizing the relative frequency, clinical overlap, and diagnostic challenges of each variant. This prospective approach provides more reliable natural history data than retrospective studies, which are subject to recall bias and heterogeneous assessment methods.

His earlier imaging work established MRI patterns that distinguish PSP subtypes from [Parkinson's Disease](/diseases/parkinsons-disease), demonstrating that brainstem and cerebellar atrophy patterns correlate with specific clinical phenotypes[@ferraro2022imaging]. Quantitative MRI analysis showed that midbrain tegmentum and superior cerebellar peduncle volumes are reduced in PSP compared to PD, with the most pronounced atrophy in the Richardson variant.

Autonomic Dysfunction in Atypical Parkinsonisms

Dr. Ferraro has conducted extensive research on autonomic dysfunction as a defining feature of [Multiple System Atrophy](/diseases/multiple-system-atrophy) and a significant contributor to disability in [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy). His 2023 study in Neurology examined the clinical correlates and prognostic implications of autonomic failure in PSP[@ferraro2023autonomic].

The study found that orthostatic hypotension, urinary dysfunction, and sudomotor impairment are independent predictors of reduced survival in PSP, and that autonomic dysfunction correlates with disease severity at baseline and with faster progression on both motor and cognitive endpoints. This work aligns with findings from MSA research, where autonomic failure is a hallmark feature, but extends the prognostic significance to PSP.

His research on the Italian MSA registry provides natural history data for MSA patients in the Italian population, including the prevalence and progression of autonomic features, sleep disorders, and parkinsonian motor signs[@cortelli2019msa]. The registry data have been used to validate clinical diagnostic criteria and to identify predictors of rapid progression.

Ocular Motor Abnormalities

Ocular motor dysfunction is a cardinal feature of PSP, and Dr. Ferraro has studied these abnormalities in detail. His 2022 paper on "Ocular motor abnormalities in progressive supranuclear palsy" used standardized examination protocols to characterize the type, frequency, and severity of oculomotor deficits across the PSP spectrum[@ferraro2022eye].

The study found that vertical supranuclear gaze palsy is not uniformly present — early-stage PSP patients may show isolated slowing of vertical saccades without frank palsy — and that horizontal gaze abnormalities emerge as disease progresses. The degree of ocular motor impairment correlates with disease duration and with specific atrophy patterns on MRI, providing clinicians with a bedside marker of disease severity.

Speech and Voice Disorders

Dr. Ferraro's acoustic analysis research on speech and voice disorders in atypical parkinsonisms has quantified the dysarthric patterns that distinguish PSP from PD and MSA[@ferraro2023speech]. Using standardized acoustic measures, his work demonstrated that PSP patients show a distinct pattern of reduced speech rate, imprecise consonant production, and monopitch compared to PD patients, with the acoustic signature correlating with disease severity and progression rate.

This research has implications for clinical assessment tools, for speech therapy interventions, and for outcome measures in clinical trials, where speech deterioration is a relevant endpoint that is often underappreciated in rating scales.

Cerebellar Phenotypes

Both [Multiple System Atrophy](/diseases/multiple-system-atrophy) and PSP can present with cerebellar signs, and Dr. Ferraro has studied these phenotypes specifically. His work on cerebellar signs in MSA documented the prevalence of nystagmus, limb ataxia, gait ataxia, and scanning speech in the cerebellar variant of MSA (MSA-C)[@ferraro2019cerebellar], and his 2024 prospective study extended this to longitudinal tracking of cerebellar deterioration in both MSA-C and PSP-C[@ferraro2024cereb].

These studies showed that cerebellar ataxia is not a static feature but progresses over time, with most MSA-C patients developing severe gait and appendicular ataxia within 5 years of symptom onset. The longitudinal data enable better prediction of disease trajectory for individual patients and provide natural history benchmarks for therapeutic trials.

Cognitive Impairment and Working Memory

Dr. Ferraro has investigated cognitive impairment across the spectrum of atypical parkinsonisms, demonstrating that frontal executive dysfunction is common in PSP and MSA, but that the severity and pattern differ from [Parkinson's Disease](/diseases/parkinsons-disease) with dementia[@ferraro2021dementia]. His N-back working memory study found that PSP patients show pronounced impairment in the 2-back condition, reflecting frontostriatal dysfunction, while MSA patients show a different pattern related to cerebellar-thalamic circuit involvement[@ferraro2018nback].

REM Sleep Behavior Disorder

Sleep disturbances, particularly [REM sleep behavior disorder](/diseases/rem-sleep-behavior-disorder) (RBD), are common in synucleinopathies like [Parkinson's Disease](/diseases/parkinsons-disease) and [MSA](/diseases/multiple-system-atrophy), but their prevalence and significance in [tauopathies](/mechanisms/4r-tauopathy-mechanisms) like PSP are less well characterized. Dr. Ferraro's study found that RBD occurs in approximately 20% of PSP patients, which is lower than in synucleinopathies but still clinically significant[@ferraro2020sleep].

Neuroimaging Biomarkers

Beyond structural MRI, Dr. Ferraro has collaborated on neuroimaging biomarker studies in atypical parkinsonisms. His 2024 review of neuroimaging approaches covered the spectrum from conventional MRI volumetry to advanced techniques including diffusion tensor imaging, quantitative susceptibility mapping, and [18F]FDG-PET metabolic imaging[@calandra2024neuroimaging]. The review provided a practical framework for integrating imaging biomarkers into clinical diagnosis and trial design.

Blood Neurofilament Light Chain

Dr. Ferraro has contributed to biomarker research using blood neurofilament light chain (NfL) as a marker of neuroaxonal injury in atypical parkinsonisms. His 2024 study showed that serum NfL levels are elevated in both PSP and MSA compared to controls and healthy aging, with higher levels predicting faster progression and reduced survival[@ferraro2024biomarkers]. The study also demonstrated that NfL levels can help differentiate PSP from PD and functional parkinsonism, though overlap between conditions limits its utility as a standalone diagnostic tool.

Dystonia in Atypical Parkinsonisms

His research on dystonia in atypical parkinsonian syndromes documented the distribution, phenomenology, and treatment responsiveness of dystonic features in PSP and MSA[@ferraro2023dystonia]. Cervical dystonia (retrocollis), blepharospasm, and limb dystonia were identified as common patterns, with botulinum toxin injection providing significant benefit for focal dystonias.

Gait and Postural Disorders

Dr. Ferraro's kinematic analysis of gait impairment in parkinsonian disorders characterized the distinctive patterns of gait freezing, postural instability, and shuffling that differentiate PSP and MSA from PD[@ferraro2021gait]. The study used instrumented walkway analysis to quantify step length, cadence, gait variability, and freezing episodes, finding that PSP patients show the greatest gait variability and most frequent freezing episodes among the atypical parkinsonisms.

Italian Movement Disorder Research Context

Italy has a rich tradition in movement disorder research, with major centers in Bologna, Rome (Sapienza and Gemelli), Milan (IRCCS Carlo Besta), Naples (Federico II), and Padua. The Italian Neurological Society's movement disorder section has facilitated multicenter collaborative studies, and the Italian MSA and PSP registries coordinated from Bologna have provided invaluable natural history data for the international research community.

Dr. Ferraro's contribution to these registries — including the Italian MSA registry, the Italian PSP registry, and participation in the PROSPER European consortium — has enabled cross-center data pooling that improves the statistical power of epidemiological studies and enables identification of regional variations in disease presentation.

Key Research Contributions Summary

| Year | Contribution | Impact |
|------|-------------|--------|
| 2017 | Stem cell approaches in neurodegenerative disease | Review of experimental and clinical perspectives[@ferraro2017stem] |
| 2018 | N-back working memory in atypical parkinsonism | Frontal dysfunction characterization[@ferraro2018nback] |
| 2019 | Cerebellar signs in MSA | Clinical and neuroimaging correlates[@ferraro2019cerebellar] |
| 2019 | Italian MSA registry | Natural history and clinical features[@cortelli2019msa] |
| 2020 | REM sleep behavior disorder in PSP | Prevalence and clinical significance[@ferraro2020sleep] |
| 2021 | Gait impairment in parkinsonian disorders | Kinematic analysis[@ferraro2021gait] |
| 2021 | Cognitive impairment across atypical parkinsonisms | Comparative study[@ferraro2021dementia] |
| 2022 | MRI patterns of atrophy in PSP subtypes | Volumetric study[@ferraro2022imaging] |
| 2022 | Ocular motor abnormalities in PSP | Prospective study[@ferraro2022eye] |
| 2023 | Autonomic dysfunction in PSP | Prognostic implications[@ferraro2023autonomic] |
| 2023 | Speech and voice disorders in atypical parkinsonism | Acoustic analysis[@ferraro2023speech] |
| 2023 | Dystonia in atypical parkinsonian syndromes | Phenotype and treatment[@ferraro2023dystonia] |
| 2024 | Clinical features of PSP variants | Italian prospective cohort[@ferraro2024clinical] |
| 2024 | Neuroimaging biomarkers in atypical parkinsonisms | Review[@calandra2024neuroimaging] |
| 2024 | Cerebellar phenotype in MSA | Longitudinal study[@ferraro2024cereb] |
| 2024 | Blood NfL in atypical parkinsonisms | Diagnostic and prognostic value[@ferraro2024biomarkers] |

Recent Research (2024-2025)

Dr. Ferraro's recent work emphasizes Italian cohort studies and biomarker development:

Selected Publications

Professional Memberships and Roles

• Italian Neurological Society (SIN) — Movement Disorder Section, active member
• Italian Registry of MSA (IRMSA) — Coordinating investigator
• Italian Registry of PSP (IRPSP) — Coordinating investigator
• PROSPER European Consortium — Italian site principal investigator
• European Reference Network for Rare Neurological Diseases (ERN-RND) — Contributing expert
• Movement Disorder Society (MDS) — International member

Stem Cell and Neuroprotective Approaches

Dr. Ferraro has reviewed and contributed to the growing literature on stem cell therapies and neuroprotective strategies for neurodegenerative diseases[@ferraro2017stem]. His work has assessed the evidence for various approaches including:

• Mesenchymal stem cell transplantation: Phase I/II trials in PD and MSA have shown safety and preliminary efficacy signals for改善 motor function
• Neural stem cell approaches: Preclinical studies showing survival and integration of transplanted neural stem cells in animal models of parkinsonism
• Neurotrophic factor delivery: Gene therapy approaches delivering GDNF or BDNF to the striatum via AAV vectors

Clinical Trial Participation and Methodology

Dr. Ferraro has participated in multiple phase II and III clinical trials for MSA and PSP therapeutics, contributing to the Italian contribution to international consortia. His experience with UMSARS-based endpoints and the MDS criteria has informed Italian participation in the European MSA Initiative (EMSA-I) clinical trial program.

He has also contributed to Italian national initiatives on rare neurological diseases through the ERN-RND framework, which facilitates cross-border patient referrals for specialized clinical care and research participation.

Teaching and Training

Dr. Ferraro has been active in medical education at the University of Bologna, teaching neurology residents and medical students about movement disorders, parkinsonian syndromes, and neurodegenerative diseases. His clinical case conferences emphasize the practical application of diagnostic criteria and the importance of systematic clinical examination.

He has also trained visiting neurologists from other Italian centers and international fellows in the use of standardized assessment tools including the UMSARS, the PSP Rating Scale (PSPRS), and the MDS-UPDRS.

Key Clinical Research Questions

Dr. Ferraro's work addresses several fundamental questions in atypical parkinsonism research:

Italian Research Network Context

Italy's movement disorder research infrastructure is among the strongest in Europe. Key features include:

• The Italian Society of Neurology (SIN) Movement Disorders Study Group: coordinates multicenter studies and clinical trial participation
• The Italian MSA and PSP registries: coordinated from Bologna, these registries provide the backbone of natural history data for Italian patients
• IRCCS network: the Istituto delle Scienze Neurologiche in Bologna holds IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) status, providing dedicated research funding and clinical infrastructure
• European collaboration: Italian centers are active members of PROSPER (PSP) and the European MSA Study Group, enabling data pooling across national boundaries

Honors and Recognition

• Italian Society of Neurology Young Investigator Award (2019)
• Best Clinical Research Paper, Italian Movement Disorder Society (2021)
• Co-author of >100 peer-reviewed publications in Movement Disorders, Neurology, Lancet Neurology, and Journal of Neurology

Professional Memberships

• Italian Neurological Society (SIN) — Movement Disorder Section
• Movement Disorder Society (MDS) — International member
• Italian Registry of MSA (IRMSA) — Coordinating Investigator
• Italian Registry of PSP (IRPSP) — Coordinating Investigator
• PROSPER European Consortium — Italian Site PI
• ERN-RND — Contributing expert
• European Academy of Neurology (EAN) — Active member

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau)
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Gunter Höglinger](/researchers/gunter-hoglinger)
• [Gregor Wenning](/researchers/werner-wenning)